Patents by Inventor Tobias Wunberg

Tobias Wunberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250129095
    Abstract: The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, L, U, V and W have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: April 24, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • Publication number: 20250019385
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, ring A, ring B, p, q, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 29, 2024
    Publication date: January 16, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Juergen RAMHARTER, Dhruba SARKAR, Kevin SOKOL, Alex WATERSON, Tobias WUNBERG
  • Publication number: 20250002504
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 26, 2024
    Publication date: January 2, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • Publication number: 20240358688
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 27, 2024
    Publication date: October 31, 2024
    Inventors: Harald ENGELHARDT, Mark PETRONCZKI, Juergen RAMHARTER, Ulrich REISER, Heinz STADTMUELLER, Dirk SCHARN, Tobias WUNBERG
  • Patent number: 12064421
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: August 20, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Mark Petronczki, Juergen Ramharter, Ulrich Reiser, Heinz Stadtmueller, Dirk Scharn, Tobias Wunberg
  • Patent number: 12060367
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: August 13, 2024
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, VANDERBILT UNIVERSITY
    Inventors: Joachim Broeker, Jason Abbott, Jianwen Cui, Stephen W. Fesik, Julian Fuchs, Andreas Gollner, Lorenz Herdeis, Tim Hodges, Andrew Little, Andreas Mantoulidis, Jason Phan, Juergen Ramharter, Dhruba Sarkar, Christian Alan Paul Smethurst, Kevin Sokol, Heinz Stadtmueller, Qi Sun, Matthias Treu, Alex Waterson, Birgit Wilding, Tobias Wunberg
  • Patent number: 12053473
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: August 6, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Kessler, Christiane Kofink, Matthew Russell Netherton, Juergen Ramharter, Tobias Wunberg
  • Publication number: 20240174690
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 9, 2023
    Publication date: May 30, 2024
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • Patent number: 11814380
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg, Marco Hans Hofmann, Anke Baum, Michael Gmachl, Dorothea Ingrid Rudolph, Fabio Savarese, Markus Ostermeier, Markus Frank, Annika Gille, Stefan Goepper, Marco Santagostino, Julian Wippich
  • Publication number: 20230227470
    Abstract: The present invention encompasses compounds of formula (I) wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Joachim BROEKER, Jason ABBOTT, Jianwen CUI, Stephen W. FESIK, Julian FUCHS, Andreas GOLLNER, Lorenz HERDEIS, Tim HODGES, Andrew LITTLE, Andreas MANTOULIDIS, Jason PHAN, Juergen RAMHARTER, Dhruba SARKAR, Christian Alan Paul SMETHURST, Kevin SOKOL, Heinz STADTMUELLER, Qi SUN, Matthias TREU, Alex WATERSON, Birgit WILDING, Tobias WUNBERG
  • Publication number: 20220133734
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventors: Harald ENGELHARDT, Mark PETRONCZKI, Juergen RAMHARTER, Ulrich REISER, Heinz STADTMUELLER, Dirk SCHARN, Tobias WUNBERG
  • Publication number: 20210177851
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 22, 2020
    Publication date: June 17, 2021
    Inventors: Michael GMACHL, Michael SANDERSON, Dirk KESSLER, Christiane KOFINK, Matthew Russell NETHERTON, Juergen RAMHARTER, Tobias WUNBERG, Marco HOFMANN, Fabio SAVARESE, Anke BAUM, Dorothea RUDOLPH
  • Patent number: 10898487
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Kessler, Christiane Kofink, Matthew Russell Netherton, Juergen Ramharter, Tobias Wunberg
  • Publication number: 20210009588
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Patent number: 10829487
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 10, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg
  • Patent number: 10576064
    Abstract: The present invention relates to compounds of formula (I) wherein the groups R1 to R3, R7, U, V, W, X, Y, n and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Andreas Gollner, Juergen Ramharter, Tobias Wunberg
  • Publication number: 20190358230
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Inventors: Michael GMACHL, Michael SANDERSON, Dirk KESSLER, Christiane KOFINK, Matthew Russell NETHERTON, Juergen RAMHARTER, Tobias WUNBERG, Marco HOFMANN, Fabio SAVARESE, Anke BAUM, Dorothea RUDOLPH
  • Publication number: 20190194192
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Patent number: 10138251
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Tobias Wunberg
  • Patent number: RE49698
    Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 17, 2023
    Assignee: AIC246 AG & Co. KG
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jorg Keldenich, Dieter Lang, Peter Nell